Accent Capital Management’s AstraZeneca AZN Stock Holding History

Accent Capital Management’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$166K	Sell	878 -27	-3%	-$5.08K	0.07%	84
2026 Q1	$178K	Buy	905 +405	+81%	+$78.1K	0.09%	49
2025 Q4	$91.9K	Hold	500	–	–	0.04%	66
2025 Q3	$76.7K	Hold	500	–	–	0.03%	75
2025 Q2	$69.9K	Hold	500	–	–	0.03%	82
2025 Q1	$73.5K	Hold	500	–	–	0.04%	81
2024 Q4	$65.5K	Sell	500 -121	-19%	-$16.9K	0.04%	72
2024 Q3	$96.7K	Hold	621	–	–	0.06%	75
2024 Q2	$96.8K	Buy	621 +63	+11%	+$9.48K	0.06%	74
2024 Q1	$75.5K	Hold	558	–	–	0.07%	63
2023 Q4	$75.1K	Buy	+558	New	+$72.5K	0.06%	80

Other funds holding AZN

Evelyn Partners London $46.9B AUM

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Accent Capital Management's AZN Position: Q2 2026 in Review

Accent Capital Management reduced its AstraZeneca (AZN) stake by 3% in Q2 2026, selling an estimated $5.08K and leaving 878 shares worth $166K. The position accounts for 0.07% of the portfolio, ranked #84.

Accent Capital Management first reported a position in AZN in Q4 2023 and has held it in 11 quarters since. The position peaked at $178K in Q1 2026. 1,502 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

Accent Capital Management held 878 shares of AstraZeneca worth $166K as of Q2 2026.
Accent Capital Management sold 27 AstraZeneca shares in Q2 2026, an estimated $5.08K.
AstraZeneca made up 0.07% of Accent Capital Management's portfolio in Q2 2026, its #84 holding.
Accent Capital Management first reported a position in AstraZeneca in Q4 2023 and has held it in 11 quarters since.
Accent Capital Management's AstraZeneca position peaked at $178K in Q1 2026.
1,502 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Accent Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.